Ray Page, DO, PhD, FACOI, FASCO

Research Reports

Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting

02/15/2018

Michael A. Savin , MD;

Ravi Salgia , MD, PhD;

Blase Polite , MD;

Corey Shamah , MD;

Mark A. Socinski , MD;

Amanda Barry , MPH;

Kathy Lokay ;

Peter G. Ellis , MD;

Casey Mason ;

Ray Page , DO, PhD, FACOI, FASCO;

Natalie Dickson , MD;

Abstract: Despite clear clinical benefit and guideline recommendations for predictive biomarker testing and subsequent first-line targeted therapy treatment in patients with non–small cell lung cancer (NSCLC), there...

...

02/15/2018

Journal of Clinical Pathways

Perspectives

The Challenge of Developing Pathways in a Rapidly Evolving Clinical Space: Chronic Lymphocytic Leukemia as a Case Study

03/16/2020

Ray Page , DO, PhD, FACOI, FASCO;

Andrew Hertler , MD, FACP;

Steve L. D'Amato , BSPharm, BCOP;

Michael Kolodziej , MD;

Barry Brooks , MD;

William A. Flood , MD, MS;

Abstract: Clinical pathways represent an effort to optimize value-based clinical decision making by standardizing (when appropriate) evidence-based care to offer patients the best outcome while remaining mindful of...

...

03/16/2020

Journal of Clinical Pathways

Perspectives

Individualized Care Through Treatment Pathways: Isn’t This an Oxymoron?

06/26/2024

Ray Page , DO, PhD, FACOI, FASCO;

This article describes how congruent solutions for treatment options can be achieved if the objectives of precision medicine and treatment pathways are aligned.

This article describes how...

06/26/2024

Journal of Clinical Pathways